866-997-4948(US-Canada Toll Free)

Alpha Mannosidosis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Published By :

Transparency Market Research

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 109 Pages

Global Alpha Mannosidosis Market: Overview

With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited condition that leads to problems in organs and tissues of the body. The disease is of three types such as Type I, Type II and Type III.  Type I is a mild form, type II is moderate form of disease and most commonly observed, whereas, type III is the severe form of disease. Alpha Mannosidosis affects 1 in every 10, 00,000 people worldwide. Alpha-mannosidosis affects men and women equally across the globe. Bone marrow transplant (BMT) and Enzyme replacement therapy (ERT) are the two treatment options for alpha mannosidosis. Bone marrow transplant (BMT) has been conventionally used universally to treat patients suffering from alpha mannosidosis.

Some of the factors driving this market include market exclusivity of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment etc. However, the factors such as high cost of orphan drugs and lack of awareness are expected to hamper the market demand.

Global Alpha Mannosidosis Market: Segmentation

The alpha mannosidosis market has been segmented based on treatment, indication, end-user and geography. Based on treatment, the market has been segmented into bone marrow transplant (BMT) and enzyme replacement therapy (ERT). Enzyme replacement therapy (ERT) is expected to dominate the market with a considerable share in 2017. With the expected increase in the incidence of alpha mannosidosis the market is expected to grow at a high rate in the next few years. BMT is expected to grow steadily due to the morbidity issues connected with the treatment. In terms of indication, the market has been categorized into type I, type II and type III. The market for type III segment is projected to expand at the maximum rate during the forecast period. Type II accounts for a considerable market share at present. Based on end-user, the market has been segmented into hospitals and specialty clinics. The hospitals segment dominated the market and the trend is likely to continue driven by increasing patient burden due to rise in patient burden.

Global Alpha Mannosidosis Market: Regional Outlook

Geographically, the market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific is expected to dominate the market in 2017 with a considerable market share. North America and Europe also account for substantial portion of the market. The report identifies and explains key market drivers, restraints and opportunities. The report also provides Porter’s five forces analysis for comprehensive market understanding. Furthermore, market attractiveness analysis provides insights to most attractive regional markets to invest in the future.

Key Players Mentioned in this Research Report are:

Zymenex, a company focused on R&D on biologics designed to fight rare and life-threatening genetic diseases has developed recombinant enzyme indicated for patients with alpha-Mannosidosis known as Lamazym (velmanase alfa). Zymenex has been acquired by Chiesi Farmaceutici S.p.A. Lamazym has received orphan drug designation is Europe and the U.S.

The alpha mannosidosis market has been segmented as follows:

  • Alpha Mannosidosis Market, by Treatment
  • Bone Marrow Transplant (BMT)
  • Enzyme Replacement Therapy (ERT)
     
  • Alpha Mannosidosis Market, by Indication
  • Type I
  • Type II
  • Type III
     
  • Alpha Mannosidosis Market, by End-user
  • Hospitals
  • Specialty Clinics
     
  • Alpha Mannosidosis Market, by Geography
  • Introduction
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Alpha Mannosidosis Market

4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Alpha Mannosidosis Market Analysis and Forecasts, 2014-2024
4.3.1. Pricing - Actuals and Projections, 2014-2024 (US$ per Unit)
4.4. Porter’s Five Force Analysis
4.5. Market Outlook

5. Alpha Mannosidosis Market Analysis and Forecasts, By Treatment
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Size (US$ Mn) Forecast By Treatment
5.4.1. Bone Marrow Transplant (BMT)
5.4.2. Enzyme Replacement Therapy (ERT)
5.5. Market Attractiveness By Treatment

6. Alpha Mannosidosis Market Analysis and Forecasts, By Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Size (US$ Mn) Forecast By Indication
6.4.1. Type I
6.4.2. Type II
6.4.3. Type III
6.5. Market Attractiveness By Indication

7. Alpha Mannosidosis Market Analysis and Forecasts, By End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By End-user
7.4.1. Hospitals
7.4.2. Specialty Clinics
7.5. Market Attractiveness By End-user

8. Alpha Mannosidosis Market Analysis and Forecasts, By Geography
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Geography
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East and Africa
8.5. Market Attractiveness By End-user

9. Competition Landscape
9.1. Market Player – Competition Matrix (By Tier and Size of companies)
9.2. Market Share Analysis By Company (2015)
9.3. Company Profiles
9.3.1. Zymenex (Chiesi Farmaceutici S.p.A.)
9.3.1.1 Overview
9.3.1.2 Financials
9.3.1.3 Recent Developments
9.3.1.4 Strategy

List of Table

Table No. 1 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Treatment, 2017–2024
Table No. 2 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Indication, 2017–2024
Table No. 3 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By End-user, 2017–2024
Table No. 4 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Geography, 2017–2024
Table No. 5 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2017– 2024
Table No. 6 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2017– 2024
Table No. 7 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2017– 2024
Table No. 8 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2017– 2024
Table No. 9 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication, 2017– 2024
Table No. 10 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2017– 2024
Table No. 11 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2017– 2024
Table No. 12 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2017– 2024
Table No. 13 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2017– 2024
Table No. 14 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2017– 2024
Table No. 15 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2017– 2024
Table No. 16 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2017– 2024
Table No. 17 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2017– 2024
Table No. 18 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2017– 2024
Table No. 19 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2017– 2024

List of Chart

Figure 01 Alpha Mannosidosis Market Snapshot
Figure 02 Alpha Mannosidosis Market Size (US$ Mn) and Forecast, 2017–2024
Figure 03 Alpha Mannosidosis Treatment Market Revenue (US$ Mn) and Y-o-Y growth (%), Bone Marrow Transplant (BMT) 2017–2024
Figure 04 Alpha Mannosidosis Treatment Market Revenue (US$ Mn) and Y-o-Y growth (%),Enzyme Replacement Therapy (ERT) 2017–2024
Figure 05 Alpha Mannosidosis Market Attractiveness Analysis By Treatment
Figure 06 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%),Type I, 2017–2024
Figure 07 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%),Type II, 2017–2024
Figure 08 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%), Type III, 2017–2024
Figure 09 Alpha Mannosidosis Market Attractiveness Analysis By Indication
Figure 10 Alpha Mannosidosis End-user Market Revenue (US$ Mn) and Y-o-Y growth (%),Hospitals, 2017–2024
Figure 11 Alpha Mannosidosis End-user Market Revenue (US$ Mn) and Y-o-Y growth (%),Specialty Clinics, 2017–2024
Figure 12 Alpha Mannosidosis Market Attractiveness Analysis By End-user
Figure 13 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%), North America, 2017–2024
Figure 14 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Europe, 2017–2024
Figure 15 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Asia Pacific, 2017–2024
Figure 16 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Latin America, 2017–2024
Figure 17 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Middle East & Africa, 2017–2024
Figure 18 North America Alpha Mannosidosis Value Share Analysis, By Treatment, 2017 and 2024
Figure 19 North America Alpha Mannosidosis Value Share Analysis, By Indication, 2017 and 2024
Figure 20 North America Alpha Mannosidosis Value Share Analysis, By End-user, 2017 and 2024
Figure 21 Europe Alpha Mannosidosis Value Share Analysis, By Treatment, 2017 and 2024
Figure 22 Europe Alpha Mannosidosis Value Share Analysis, By Indication, 2017 and 2024
Figure 23 Europe Alpha Mannosidosis Value Share Analysis, By End-user, 2017 and 2024
Figure 24 Asia Pacific Alpha Mannosidosis Value Share Analysis, By Treatment, 2017 and 2024
Figure 25 Asia Pacific Alpha Mannosidosis Value Share Analysis, By Indication, 2017 and 2024
Figure 26 Asia Pacific Alpha Mannosidosis Value Share Analysis, By End-user, 2017 and 2024
Figure 27 Latin America Alpha Mannosidosis Value Share Analysis, By Treatment, 2017 and 2024
Figure 28 Latin America Alpha Mannosidosis Value Share Analysis, By Indication, 2017 and 2024
Figure 29 Latin America Alpha Mannosidosis Value Share Analysis, By End-user, 2017 and 2024
Figure 30 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By Treatment, 2017 and 2024
Figure 31 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By Indication, 2017 and 2024
Figure 32 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By End-user, 2017 and 2024

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *